伊立替康联合FP方案治疗晚期食管癌疗效分析.doc

1 伊立替康联合 FP 方案治疗晚期食管癌疗效分析【摘要】目的评价伊立替康联合 FP 方案( PIF ) 和顺铂联合***尿嘧啶(PF) 方案治疗晚期食管癌的疗效及毒副反应。方法 73 例确诊晚期食管癌患者, 随机分为两组, PF 方案组 36 例, PIF 方案组 37 。每 21d为1 周期,每 2 周期评价疗效。结果 73 例均可评价疗效, PIF 方案组总有效率 %, PF 案组总有效率 % ,两组近期疗效比较,差异无统计学意义。 PIF 方案组平均疾病进展时间 TTP 个月,平均生存期 个月; PF 组平均疾病进展时间 TTP 个月,平均生存期 个月。 PIF 方组一年生存率 % ,亦明显高于 PF 方案组 % 。主要的毒副作用为恶心呕吐、骨髓抑制、腹泻。腹泻发生率二组之间比较差异具有统计学意义( ) ;其余二组之间比较差异均无统计学意义。两组病例均无化疗相关性死亡。结论 PIF 方案疗效要优于 PF 方案, 毒副反应临床上可以接受, 不失为晚期食管癌患者的一种选择。蕌【关键词】伊立替康;晚期食管癌;化疗 Clinical study of irinotecan bination with PF in 2 treatmeant of advanced esophageal cancer ZHANG Jing 拟 wEi,DUAN Dong 拟 mEI,REN Zhong 拟 hai. Department of Oncology, Nan Yang Central Hospital, HeNan 473000, China 蕌【 Abstract 】 Objective To evaluate the efficacy and adverse events of irinotecan ( CPT 拟 11) combined with PF in the treatmentof patients with advanced esophageal cancer. Methods A totalof 73 cases with advanced esophageal entered this patientswere randomly divided into trial group and control group, and 37 cases received chemotherapy of PIF cases received chemotherapy of PF patient received at least 2 cyclesof chemotherapy. Results The efficacy and adverse events were evaluated in all patients. The overall response ratewas % in the PIF group and % in the PF group, the difference between the two groups did not reach statistical